Novacta Biosystems has commenced dosing of the first healthy volunteers in a phase 1 clinical trial of a new antibiotic to treat the hospital superbug Clostridium difficile.
This website uses cookies
We inform you that this site uses own, technical and third parties cookies to make sure our web page is user-friendly and to guarantee a high functionality of the webpage. By continuing to browse this website, you declare to accept the use of cookies.